NEW YORK, N.Y. -- A collaborative formed by Autism Speaks, the world's leading autism science and advocacy organization, has found full genome sequencing examining the entire DNA code of individuals with autism spectrum disorder (ASD) and their family members to provide the definitive look at the wide ranging genetic variations associated with ASD. The study published online today in American Journal of Human Genetics, reports on full genome sequencing on 32 unrelated Canadian individuals with autism and their families, participants in the Autism Speaks Autism Genetic Resource Exchange (AGRE). The results include both inherited as well as spontaneous or de novo, genetic alterations found in one half of the affected families sequenced.
This dramatic finding of genetic risk variants associated with clinical manifestation of ASD or accompanying symptoms in 50 percent of the participants tested is promising, as current diagnostic technology has only been able to determine a genetic basis in about 20 percent of individuals with ASD tested. The large proportion of families identified with genetic alterations of concern is in part due to the comprehensive and uniform ability to examine regions of the genome possible with whole genome sequencing missed in other lower resolution genome scanning approaches.
"From diagnosis to treatment to prevention, whole genome sequencing efforts like these hold the potential to fundamentally transform the future of medical care for people with autism," stated Autism Speaks Chief Science Officer and study co-author Robert Ring, Ph.D.
The study identified genetic variations associated with risk for ASD including de novo, X-linked and other inherited DNA lesions in four genes not previously recognized for ASD; nine genes previously determined to be associated with ASD risk; and eight candidate ASD risk genes. Some families had a combination of genes involved. In addition, risk alterations were found in genes associated with fragile X or related syndromes (CAPRIN1 and AFF2), social-cognitive deficits (VIP), epilepsy (SCN2A and KCNQ2) as well as NRXN1 and CHD7, which causes ASD-associated CHARGE syndrome.
"Whole genome sequencing offers the ultimate tool to advance the understanding of the genetic architecture of autism," added lead author Dr. Stephen Scherer, senior scientist and director of the Centre for Applied Genomics at The Hospital for Sick Children (SickKids) and director of the McLaughlin Centre at the University of Toronto. "In the future, results from whole genome sequencing could highlight potential molecular targets for pharmacological intervention, and pave the way for individualized therapy in autism. It will also allow for earlier diagnosis of some forms of autism, particularly among siblings of children with autism where recurrence is approximately 18 per cent."
This $1 million collaboration of Autism Speaks, SickKids, BGI and Duke University piloted Autism Speaks' initiative to generate the world's largest library of sequenced genomes of individuals with ASD announced in late 2011. "As we continue to test more individuals and their family members from the AGRE cohort, we expect to discover and study additional genetic variants associated with autism. This collaboration will accelerate basic and translational research in autism and related developmental disabilities," concluded Autism Speaks Vice President for Scientific Affairs Andy Shih, Ph.D. who oversees the collaboration, "and this collection of sequenced genomes will facilitate new collaborations engaging researchers around the world, and enable public and private entities to pursue pivotal research."
In this pilot effort, a total of 99 individuals were tested, including the 32 individuals with ASD (25 males and seven females) and their two parents, as well as three members of one control family not on the autism spectrum. Using families in the Autism Speaks AGRE collection, this Autism Speaks initiative will ultimately perform whole genome sequencing on more than 2,000 participating families who have two or more children on the autism spectrum. The data from the 10,000 AGRE participants will enable new research in the genomics of ASD, and significantly enhance the science and technology networks of Autism Speaks and its collaborators.
This work was supported by Autism Speaks, Autism Speaks Canada, Autism Speaks Autism Genome Resource Exchange (AGRE), National Institutes of Health (NIH), National Science and Technology Ministry Project -973 program, National Science and Technology Ministry Project -863 program, National Natural Science Foundation of China-Major Program, the Shenzhen Municipal Government of China, Enterprise Key Laboratory Supported by Guangdong Province, Shenzhen Key Laboratory of Gene Bank for National Life Science (National Gene Bank Project of China), NeuroDevNet, the Canadian Institutes for Advanced Research, the University of Toronto McLaughlin Centre, Genome Canada/ Ontario Genomics Institute, the government of Ontario, the Canadian Institutes of Health Research (CIHR) and SickKids Foundation.
AGRE is a research program based in the U.S. designed to accelerate the pace of science by providing a ready and available data base for researchers, thereby allowing them to focus their time and efforts on analyzing the data and looking for answers rather than collecting data on a study-by-study basis. AGRE provides DNA, clinical, and medical information to autism researchers worldwide. AGRE is the world's largest private collection of multiplex autism families and is uniquely designed to allow continuing contact with the participating families to collect additional clinical data. For more information on AGRE visit the AGRE website for families and researchers.
Autism is a general term used to describe a group of complex developmental brain disorders - autism spectrum disorders - caused by a combination of genes and environmental influences. These disorders are characterized, in varying degrees, by communication difficulties, social and behavioral challenges, as well as repetitive behaviors. An estimated one in 88 children in the U.S. is on the autism spectrum - a 78 percent increase in six years that is only partly explained by improved diagnosis.
About Autism Speaks
Autism Speaks is the world's leading autism science and advocacy organization. It is dedicated to funding research into the causes, prevention, treatments and a cure for autism; increasing awareness of autism spectrum disorders; and advocating for the needs of individuals with autism and their families. Autism Speaks was founded in February 2005 by Suzanne and Bob Wright, the grandparents of a child with autism. Mr. Wright is the former vice chairman of General Electric and chief executive officer of NBC and NBC Universal. Since its inception, Autism Speaks has committed nearly $199 million to research and developing innovative resources for families. Each year Walk Now for Autism Speaks events are held in more than 95 cities across North America. On the global front, Autism Speaks has established partnerships and related activities in more than 40 countries on 5 continents to foster international research, services and awareness. To learn more about Autism Speaks, please visit http://www.